

AARC Clinical Practice Guideline

Bronchoscopy Assisting—2007 Revision & Update

BA 1.0 PROCEDURE

The role of the assistant in Bronchoscopy Assisting (BA)

BA 2.0 DESCRIPTION/DEFINITION

Bronchoscopy, fiberoptic or rigid, is an invasive procedure for visualization of the upper and lower respiratory tract for the diagnosis and management of a spectrum of inflammatory, infectious, and malignant diseases of the airway and lungs.^{1,2} Bronchoscopy may include retrieval of tissue specimens (bronchial brush, forceps, and needle), cell washings, bronchoalveolar lavage, coagulation, or removal of abnormal tissue by laser. Bronchoscopy is widely used as a diagnostic and therapeutic tool for management of the airway.³ Bronchoscopy is performed by a specially trained physician bronchoscopist and is assisted by a specially trained health-care professional (HCP). This guideline addresses the role of the HCP in bronchoscopy assistance (BA)⁴ (Section 10.3).

BA 3.0 SETTINGS

The preferred location for bronchoscopy is determined by the available equipment, the medical condition and age of the patient, and the specific procedures to be performed.^{1,2,4} A designated bronchoscopy room or suite is the preferred location for outpatients or inpatients who are not critically ill. The procedure may be safely performed at the bedside in the intensive care unit, the operating room, an appropriately equipped outpatient facility, or other suitably equipped clinical area.^{1,2,4}

BA 4.0 INDICATIONS

Indications include but are not limited to

- 4.1 The presence of lesions of unknown etiology on the chest radiograph film or the need to evaluate recurrent pneumonia, persistent atelectasis or pulmonary infiltrates^{1,2,4-9}
- 4.2 The need to assess patency or mechanical

properties of the upper airway^{1,2,4,6,8}

4.3 The need to investigate hemoptysis, persistent unexplained cough, dyspnea, localized wheeze, or stridor^{1,2,4-8,10}

4.4 Suspicious or positive sputum cytology results^{1,2,4-6}

4.5 The need to obtain lower respiratory tract secretions, cell washings, and biopsies for cytologic, histologic, and microbiologic evaluation^{1,2,4,7,9,11,12}

4.6 The need to determine the location and extent of injury from toxic inhalation or aspiration^{1,2,4,6}

4.7 The need to evaluate problems associated with endotracheal or tracheostomy tubes (tracheal damage, airway obstruction, or tube placement)^{1,2,4-7}

4.8 The need for aid in performing difficult intubations or percutaneous tracheostomies^{1,2,4,6,7}

4.9 The suspicion that secretions or mucus plugs are responsible for lobar or segmental atelectasis^{1,2,4-6}

4.10 The need to remove abnormal endobronchial tissue or foreign material by forceps, basket, or laser^{1,2}

4.11 The need to retrieve a foreign body (although under most circumstances, rigid bronchoscopy is preferred)^{6,7,13}

4.12 Therapeutic management of endobronchial toilet in ventilator associated pneumonia¹⁴

4.13 Achieving selective intubation of a main stem bronchus¹⁴

4.14 The need to place and/or assess airway stent function¹⁴

4.15 The need for airway balloon dilatation in treatment of tracheobronchial stenosis^{15,16}

BA 5.0 CONTRAINDICATIONS

Flexible bronchoscopy should be performed only when the relative benefits outweigh the risks.

5.1 Absolute contraindications include

5.1.1 Absence of consent from the patient or his/her representative unless a medical emergency exists and patient is not competent to give permission^{1,2}

5.1.2 Absence of an experienced bronchoscopist to perform or closely and directly supervise the procedure^{1,2,4}

5.1.3 Lack of adequate facilities and personnel to care for such emergencies such as cardiopulmonary arrest, pneumothorax, or bleeding^{1,2,4}

5.1.4 Inability to adequately oxygenate the patient during the procedure^{1,2}

5.2 The danger of a serious complication from bronchoscopy is especially high in patients with the disorders listed, and these conditions are usually considered absolute contraindications unless the risk-benefit assessment warrants the procedure^{1,2,4}

5.2.1 Coagulopathy or bleeding diathesis that cannot be corrected^{1,2,4}

5.2.2 Severe refractory hypoxemia^{1,2,4}

5.2.3 Unstable hemodynamic status including dysrhythmias^{1,2,4}

5.3 Relative contraindications (or conditions involving increased risk), according to the American Thoracic Society Guidelines for Fiberoptic Bronchoscopy in adults,^{1,2} include

5.3.1 Lack of patient cooperation

5.3.2 Recent (within 6 weeks) myocardial infarction or unstable angina¹⁷

5.3.3 Partial tracheal obstruction

5.3.4 Moderate-to-severe hypoxemia or any degree of hypercarbia

5.3.5 Uremia and pulmonary hypertension (possible serious hemorrhage after biopsy)

5.3.6 Lung abscess (danger of flooding the airway with purulent material)

5.3.7 Obstruction of the superior vena cava (possibility of bleeding and laryngeal edema)

5.3.8 Debility and malnutrition

5.3.9 Disorders requiring laser therapy, biopsy of lesions obstructing large airways, or multiple transbronchial lung biopsies

5.3.10 Known or suspected pregnancy (safety concern of possible radiation exposure)

5.4 The safety of bronchoscopic procedures in asthmatic patients is a concern, but the presence of asthma does not preclude the use of these procedures^{11,18}

5.5 Recent head injury patients susceptible to increased intracranial pressures¹⁹

5.6 Inability to sedate (including time constraints of oral ingestion of solids or liquids)¹⁷

BA 6.0 HAZARDS/COMPLICATIONS

6.1 Adverse effects of medication used before and during the bronchoscopic procedure^{4,7,20,21}

6.2 Hypoxemia^{4,22}

6.3 Hypercarbia

6.4 Bronchospasm²³

6.5 Hypotension²⁴

6.6 Laryngospasm, bradycardia, or other vagally mediated phenomena^{4,7,20}

6.7 Mechanical complications such as epistaxis, pneumothorax, and hemoptysis^{7,20,23,25}

6.8 Increased airway resistance^{4,26}

6.9 Death²⁷

6.10 Infection hazard for health-care workers or other patients²⁸⁻³¹ (see also Section 13)

6.11 Cross-contamination of specimens or bronchoscopes²⁸⁻³¹

6.12 Nausea, vomiting²³

6.13 Fever and chills²³

6.14 Cardiac dysrhythmias³²

BA 7.0 LIMITATIONS/VALIDATION OF RESULTS

7.1 Bronchoscopy should not be performed in patients who have a contraindication listed in Section 5.0 of this Guideline, unless the potential benefit outweighs the risk, as determined by the physician bronchoscopist.

7.2 Poor or inadequate training of the bronchoscopy assistant or bronchoscopist

7.2.1 The techniques of premedication for bronchoscopic examination

7.2.2 Function and preparation of bronchoscope and related equipment

7.2.3 Physical and physiologic monitoring during the procedure

7.2.4 Specimen retrieval (biopsies and washings), preparation of specimens, and site documentation

7.2.5 Post-procedure care of the patient

BA 8.0 ASSESSMENT OF NEED:

Need is determined by bronchoscopist assessment of the patient and treatment plan in addition to the presence of clinical indicators as described in Section 4.0, and by the absence of contraindications as described in Section 5.0.^{1,2,4}

BA 9.0 ASSESSMENT OF OUTCOME:

Patient outcome is determined by clinical, physiologic, and pathologic assessment. Procedural outcome is determined by the accomplishment of the procedural goals as indicated in Section 4.0, and by quality assessment indicators listed in Section 11.0.

BA 10.0 RESOURCES**10.1 Equipment****10.1.1 Bronchoscopic devices**

10.1.1.1 The appropriate bronchoscope size is determined by the bronchoscopist, based on the patient age⁷; this includes selecting appropriate suction and biopsy valves

10.1.1.2 Bronchoscopic light source, and any related video or photographic equipment, if applicable

10.1.1.3 Cytology brushes, flexible forceps, transbronchial aspiration needles, retrieval baskets (Compatibility of the external diameter of all scope accessories with the internal diameter of the bronchoscope should be verified before the procedure.)

10.1.1.4 Specimen-collection devices, fixatives, and as determined by institutional policies

10.1.1.5 Syringes for medication delivery, normal saline lavage, and needle aspiration

10.1.1.6 Bite block

10.1.1.7 Laryngoscope

10.1.1.8 Endotracheal tubes in various sizes

10.1.1.9 Thoracostomy set/tray

10.1.1.10 Venous access equipment (I.V. supplies)

10.1.1.11 Laryngeal mask airway³³

10.1.1.12 Adaptor with ability to connect mechanical ventilator and bronchoscope simultaneously

10.1.1.13 Sterile gauze for intermit-

tently clearing tip of bronchoscope during procedure

10.1.1.14 Appropriate procedure documentation paperwork, including laboratory requisitions

10.1.1.15 Water-soluble lubricant or lubricating jelly

10.1.2 Monitoring devices

10.1.2.1 Pulse oximeter

10.1.2.2 Electrocardiographic monitoring equipment

10.1.2.3 Sphygmomanometer

10.1.2.4 Whole-body radiation badge for personnel if fluoroscopy is used

10.1.2.5 Capnograph

10.1.3 Procedure room equipment

10.1.3.1 Oxygen and related delivery equipment

10.1.3.2 Resuscitation equipment

10.1.3.3 Medical vacuum systems (wall or portable) and related suction supplies for scope or mouth

10.1.3.4 Infection control devices as listed in Section 13.0

10.1.3.5 Fluoroscopy equipment including personal protection devices if warranted

10.1.3.6 Laser equipment if applicable

10.1.3.7 Adequate ventilation and other measures to prevent transmission of tuberculosis³⁴

10.1.4 Decontamination area equipment

10.1.4.1 Protease enzymatic agent (eg, Protozyme) for cleaning and removal of blood and protein before disinfection or sterilization, or other detergent capable of removing these substances³⁵

10.1.4.2 High-level disinfection or sterilization agent: 2% alkaline glutaraldehyde (eg, Cidex, Metracide, Sonacide, Glutarex), ethylene oxide,^{30,36} or peracetic acid³⁷

10.1.4.3 Sterile water is preferred, if feasible, for rinsing bronchoscopes. Following this rinsing with isopropyl alcohol³⁸

10.2 Medications: Institutional policies and personal preferences of the bronchoscopist vary greatly regarding the type and method of premeditation for bronchoscopic examination. Ad-

ministration of these medications by intravenous or intramuscular routes is limited to nurses, physicians, or other trained personnel. (The training and certification of “other personnel” is institution specific, should be consistent with institutional policies, and may include the respiratory therapist.) Aerosolized or atomized drugs, or drugs instilled through the bronchoscope, may be delivered by the respiratory therapist or other trained assistants.

10.2.1 Topical anesthetic (lidocaine 1%, 2%, 4%, benzocaine 14%)^{5,7,39,40}

10.2.2 Anticholinergic agent to reduce secretions and minimize vaso-vagal reflexes (atropine, glycopyrrolate)^{5,39}

10.2.3 Sedative agent 30–45 min prior to the procedure (eg, codeine, midazolam, morphine, hydroxyzine)^{5,39}

10.2.4 Intravenous sedative immediately prior to and/or during the procedure (midazolam, propofol, diazepam, fentanyl)^{5,6,39,41,42}

10.2.5 Benzodiazepine antagonist (flumazenil),⁴ narcotic antagonist (Narcan)⁴¹

10.2.6 Sterile nonbacteriostatic 0.9% NaCl solution for bronchial washings or lavage²²

10.2.7 Vasoconstrictor for bleeding control (dilute epinephrine, usually 1:10,000)^{43,44}

10.2.8 Inhaled β agonist (albuterol, metaproterenol, levalbuterol)⁴⁰

10.2.9 Water-soluble lubricant, or combined lubricant/anesthetic (viscous lidocaine)^{7,36,39}

10.2.10 Nasal decongestants (pseudoephedrine)²

10.2.11 Mucolytics or mucokinetics (10% or 20% acetylcysteine, 7.5% sodium bicarbonate, rhDNAse)⁴⁵

10.2.12 Emergency and resuscitation drugs as deemed appropriate by institutional policies

10.3 Personnel: The precise role of the bronchoscopy assistant varies among institutions;^{4,5,7,46} however, the prime responsibilities include preparation and monitoring of the patient, assisting with the procedure, handling specimens, post-procedure care of the patient,

maintenance of the bronchoscopy equipment, and recordkeeping.

10.3.1 Bronchoscopy assisting should occur only under the direction of a physician who has been trained in bronchoscopy according to the Guidelines endorsed by the American Thoracic Society^{1,2,4}

10.3.2 Bronchoscopy assisting should be limited to personnel who possess the skills necessary to determine adverse reactions and to undertake the appropriate remedial action

10.3.3 The bronchoscopy assistant must be trained in the setup, handling, cleaning, and care of bronchoscopy equipment and related supplies; specimen retrieval and preparation for commonly ordered laboratory studies on bronchoscopy specimens; biopsy labeling; delivery of aerosolized drugs; and mechanical ventilation. The assistant must also be trained in monitoring and evaluating the patient’s clinical condition as reflected by pulse oximetry, capnography, electrocardiogram, and stability of or changes in mechanical ventilation parameters, and be capable of relating changes in clinical condition to disease state, procedure, or drugs administered for the procedure. Assistants should be versed in CDC ventilation requirements for control of tuberculosis transmission. Bronchoscopy assistants should hold one of the following credentials: Certified Respiratory Therapist (CRT), Registered Respiratory Therapist (RRT), Certified Pulmonary Function Technologist (CPFT), Registered Pulmonary Function Technologist (RPFT), Registered Nurse (RN), Licensed Practical Nurse (LPN), physician (MD or DO), or Certified Surgical Technologist (CST).

BA 11.0 MONITORING

Patient monitoring should be done before, at regular intervals during, and after bronchoscopy until the patient meets appropriate discharge criteria. For no or minimal sedation, less monitoring is necessary. For moderate and deep sedation, more monitoring should be done.⁴⁷ The following should be

monitored before, during, and/or after bronchoscopy, continuously, until the patient returns to his pre-sedation level of consciousness.

11.1 Patient

11.1.1 Level of consciousness⁴⁶

11.1.2 Medications administered, dosage, route, and time of delivery⁴⁶

11.1.3 Subjective response to procedure (eg, pain, discomfort, dyspnea)⁴⁶

11.1.4 Blood pressure, breath sounds, heart rate, rhythm, and changes in cardiac status

11.1.5 S_pO₂, F_IO₂ and ETCO₂^{17,46,48}

11.1.6 Tidal volume, peak inspiratory pressure, adequacy of inspiratory flow, and other ventilation parameters if subject is being mechanically ventilated

11.1.7 Lavage volumes (delivered and retrieved)

11.1.8 Monitor and document site of biopsies and washings. Record which lab tests were requested on each sample

11.1.9 Periodic post-procedure follow-up monitoring of patient condition is advisable for 24-48 hours for inpatients. Outpatients should be instructed to contact the bronchoscopist regarding fever, chest pain or discomfort, dyspnea, wheezing, hemoptysis, or any new findings presenting after the procedure has been completed. Oral instructions should be reinforced by written instructions that include names and phone numbers of persons to be contacted in emergency.

11.1.10 Chest radiograph one hour after transbronchial biopsy to exclude pneumothorax⁴³

11.2 Technical Devices

11.2.1 Bronchoscope integrity (fiberoptic or channel damage, passage of leak test)³⁶

11.2.2 Strict adherence to the manufacturer's and institutional recommended procedures for cleaning, disinfection, and sterilization of the devices, and the integrity of disinfection or sterilization packaging^{35,36}

11.2.3 Smooth, unhampered operation of biopsy devices (forceps, needles, brushes)

11.3 Recordkeeping

11.3.1 Quality assessment indicators as

determined appropriate by the institution's quality assessment committee

11.3.2 Documentation of monitors indicated in Sections 11.1 and 11.2.

11.3.3 Identification of bronchoscope used for each patient

11.3.4 Annual assessment of the institutional or departmental bronchoscopy procedure, including an evaluation of quality assurance issues

11.3.4.1 Adequacy of bronchoscopic specimens (size or volume for accurate analysis, sample integrity)

11.3.4.2 Review of infection control procedures and compliance with the current guidelines for semicritical patient-care objects^{34,35}

11.3.4.3 Synopsis of complications

11.3.4.4 Control washings to assure that infection control and disinfection/sterilization procedures are adequate, and that cross-contamination of specimens does not occur

11.3.4.5 Annual review of the bronchoscopy service and all of the above listed records with the physician bronchoscopists

BA 12.0 FREQUENCY

The frequency with which bronchoscopy is repeated on a given patient should be determined by the physician bronchoscopist based on indications.

BA 13.0 INFECTION CONTROL

13.1 Standard Precautions⁴⁹

13.2 CDC Guideline for Handwashing and Hospital Environmental Control-Section 2: Cleaning, disinfecting, and sterilizing patient care equipment^{38,50,51}

13.3 CDC Guideline for preventing tuberculosis transmission³⁴

13.4 Hepatitis B vaccination for personnel

13.5 Establishment of and conformance to written protocol for infection control

Revised by Shelly Clifton RRT CPFT, University of Michigan Hospitals, Ann Arbor, Michigan, and approved by the 2006 CPG Steering Committee

Original publication: *Respir Care* 1993;38(11):1173-1178.

REFERENCES

1. Bolliger CT, Mathur PN, Beamis JF, Becker HD, Cavaliere S, Colt H, et al. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. *Eur Respir J* 2002;19(2):356-373.
2. Ernst A, Silvestri GA, Johnstone D; American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. *Chest* 2003;123(2):1693-1717.
3. Schellhase DE. Pediatric flexible airway endoscopy. *Curr Opin Pediatr* 2002;14(3):327-333.
4. Green CG, Eisenberg J, Leong A, Nathanson I, Schnapf BM, Wood RE. Flexible endoscopy of the pediatric airway. *Am Rev Respir Dis* 1992;145(1):233-235.
5. Prakash UBS, Offord KP, Stubbs SE. Bronchoscopy in North America: the ACCP survey. *Chest* 1991;100(6):1668-1675.
6. Landa JF. Indications for bronchoscopy. *Chest* 1978;73(5 Suppl):686-690.
7. Green CG. Assessment of the pediatric airway by flexible bronchoscopy. *Respir Care* 1991;36(6):555-568.
8. Zawadzka-Glos L, Chmielik M, Gabryszewska A, Zajac B. Analysis of indications for bronchoscopy in the department of paediatric otolaryngology in Warsaw, from 1998-2003. *New Med* 2003;6(2):4-11.
9. Jain P, Sandur S, Meli Y, Arrolig AC, Stoller JK, Mehta AC. Role of flexible bronchoscopy in immunocompromised patients with lung infiltrates. *Chest* 2004;125(2):712-722.
10. Selecky PA. Evaluation of hemoptysis through the bronchoscope. *Chest* 1978;73(5 Suppl):741-745.
11. Holgate ST, Wilson JR, Howarth PH. New insights into airway inflammation by endobronchial biopsy. *Am Rev Respir Dis* 1992;145(2 Pt 2):S2-S6.
12. Summary and recommendations of a workshop on the investigative use of fiberoptic bronchoscopy and bronchoalveolar lavage in asthmatic patients. *Chest* 1985;88(1):136-138.
13. Cunanan OS. The flexible fiberoptic bronchoscope in foreign body removal: experience in 300 cases. *Chest* 1978;73(5 Suppl):725-726.
14. Bush A. Bronchoscopy in paediatric intensive care. *Paediatr Respir Rev* 2003;4(1):67-73.
15. Hautmann H, Gamarra F, Pfeifer KJ, Huber RM. Fiberoptic bronchoscopic balloon dilatation in malignant tracheobronchial disease: indications and results. *Chest* 2001;120(1):43-49.
16. Mayse ML, Greenheck J, Friedman M, Kovitz KL. Successful bronchoscopic balloon dilatation of nonmalignant tracheobronchial obstruction without fluoroscopy. *Chest* 2004;126(2):634-637.
17. British Thoracic Society Bronchoscopy Guidelines Committee, a Subcommittee of Standards of Care Committee of British Thoracic Society. British Thoracic Society guidelines on diagnostic flexible bronchoscopy. *Thorax* 2001;56 Suppl 1:i1-i21.
18. Smith DL, Deshazo RD. Bronchoalveolar lavage in asthma: an update and perspective. *Am Rev Respir Dis* 1993;148(2):523-532.
19. Kerwin AJ, Croce MA, Timmons SD, Maxwell RA, Malhotra AK, Fabian TC. Effects of fiberoptic bronchoscopy on intracranial pressure in patients with brain injury: a prospective clinical study. *J Trauma* 2000;48(5):878-882; discussion 882-883.
20. Wood RE. Spelunking in the pediatric airways: explorations with the flexible fiberoptic bronchoscope. *Pediatr Clin North Am* 1984;31(4):785-799.
21. McAlpine LG, Thomson NC. Lidocaine-induced bronchoconstriction in asthmatic patients: relation to histamine airway responsiveness and effect of preservative. *Chest* 1989;96(5):1012-1015.
22. Schnapf BM. Oxygen desaturation during fiberoptic bronchoscopy in pediatric patients. *Chest* 1991;99(3):591-594.
23. Colt HG, Matsuo T. Hospital charges attributable to bronchoscopy-related complications in outpatients. *Respiration* 2001;68(1):67-72.
24. Hertz MI, Woodward ME, Gross CR, Swart M, Marcy TW, Bitterman PB. Safety of bronchoalveolar lavage in the critically ill, mechanically ventilated patient. *Crit Care Med* 1991;19(12):1526-1532.
25. Herf SM, Suratt PM. Complications of transbronchial lung biopsies. *Chest* 1978;73(5 Suppl):759-760.
26. Erry LB. Topical anesthesia for bronchoscopy. *Chest* 1978;73(5 Suppl):691-693.
27. Suratt PM, Smiddy JF, Gruber B. Deaths and complications associated with fiberoptic bronchoscopy. *Chest* 1976;69(6):747-751.
28. Webb SF, Vall-Spinosa A. Outbreak of *Serratia marcescens* associated with the flexible fiberbronchoscope. *Chest* 1975;68(5):703-708.
29. Dawson DJ, Armstrong JG, Blacklock ZM. Mycobacterial cross-contamination of bronchoscopy specimens. *Am Rev Respir Dis* 1982;126(6):1095-1097.
30. Weinstein HJ, Bone RC, Ruth WE. Contamination of a fiberoptic bronchoscope with *Proteus* species. *Am Rev Respir Dis* 1977;116(3):541-543.
31. Hanson PJV, Gor D, Clarke JR, Chadwick MV, Gazzard B, Jeffries DJ, et al. Recovery of the human immunodeficiency virus from fiberoptic bronchoscopes. *Thorax* 1991;46(6):410-412.
32. Vasic N. The role of ECG monitoring during bronchoscopy in lung cancer patients. *Support Care Cancer* 1995;3(6):402-408.
33. Yazbeck-Karam VG, Aouad MT, Baraka AS. Laryngeal mask airway for ventilation during diagnostic and interventional fiberoptic bronchoscopy in children. *Paediatr Anaesth* 2003;13(8):691-694.
34. Centers for Disease Control. Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. *MMWR* 1990;39(RR-17):1-29.
35. Culver DA, Gordon SM, Mehta AC. Infection control in the bronchoscopy suite. A review of outbreaks and guidelines for prevention. *Am J Respir Crit Care* 2003;167:1050.
36. Mehta AC, Curtis PS, Scalzitti ML, Meeker DP. The

- high price of bronchoscopy: maintenance and repair of the flexible fiberoptic bronchoscope. *Chest* 1990;98(2):448-454.
37. Prakash UBS. Does the bronchoscope propagate infection? *Chest* 1993;104(2):552-559.
 38. Centers for Disease Control and Prevention. Guidelines for preventing health-care associated pneumonia, 2003. *MMWR* 2003; 53 (RR-3): 4.
 39. Prakash UBS, Stubbs SE. The bronchoscopy survey: some reflections. *Chest* 1991;100(6):1660-1667.
 40. Kirkpatrick MB. Lidocaine topical anesthesia for flexible bronchoscopy (editorial). *Chest* 1989;96(5):965-967.
 41. Pickles J, Jeffrey M, Datta A, Jeffrey AA. Is preparation for bronchoscopy optimal? *Eur Respir J* 2003;22(2):203-206.
 42. Chhajed PN, Glanville AR. Management of hypoxemia during flexible bronchoscopy. *Clin Chest Med* 2003;24(3):511-516.
 43. Zavala DC. Pulmonary hemorrhage in fiberoptic transbronchial biopsy. *Chest* 1976;70(5):584-588.
 44. Hanson RR, Zavala DC, Rhodes ML, Keim LW, Smith JD. Transbronchial biopsy via flexible fiberoptic bronchoscope: results in 164 patients. *Am Rev Respir Dis* 1976;114(1):67-72.
 45. Durwand A, Forte V, Shemie SD. Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in mechanically ventilated child with refractory status asthmaticus. *Crit Care Med* 2000 Feb; 28 (2):560-562.
 46. American Academy of Pediatrics Committee on Drugs. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. *Pediatrics* 1992;89(6 Pt 1):1110-1115.
 47. American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. *Anesthesiology* 2002;96(4):1004-1017.
 48. American Association for Respiratory Care. AARC Clinical Practice Guideline: Pulse oximetry. *Respir Care* 1991;36(12):1406-1409.
 49. Bolyard EA, Tablan OC, Williams WW, Pearson ML, Shapiro CN, Deitchmann SD. Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol* 1998;19(6):407-463. *Erratum in Infect Control Hosp Epidemiol* 1998;19(7):493.
 50. Centers for Disease Control and Prevention. The Guidelines for hand hygiene in health-care settings, 2002. *MMWR* 2003; 51 (RR-16), 1-44.
 51. Centers for Disease Control and Prevention. Guidelines for environment infection control in health care facilities, 2003; 51 (RR-10), 5-13).

Interested persons may photocopy these Guidelines for noncommercial purposes of scientific or educational advancement. Please credit AARC and RESPIRATORY CARE Journal.

All of the AARC CPGs may be downloaded at no charge from
<http://www.RCJournal.com/>